BioLineRx (BLRX) EBT Margin (2024 - 2025)
BioLineRx (BLRX) posted EBT Margin of 1444.85% for Q4 2025, down 304.29% on a QoQ basis from 357.38% in Q3 2025, and down 144817.0% year-over-year from N/an in Q4 2024.
BioLineRx (BLRX) has 2 years of EBT Margin data on file, last reported at 1444.85% in Q4 2025.
- In Q4 2025, EBT Margin fell 144817.0% year-over-year to 1444.85%; the TTM figure through Dec 2025 stood at 639.24% (down 60669.0% YoY), while the FY2025 annual figure was 639.24%, down 60669.0% from the prior year.
- EBT Margin fell to 1444.85% in Q4 2025, from 357.38% in the prior quarter.
- Across five years, EBT Margin topped out at 3.33% in Q4 2024 and bottomed at 1444.85% in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 18.99% |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | -1,444.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,444.85% |
| Sep 30, 2025 | -357.38% |
| Jun 30, 2025 | -505.59% |
| Mar 31, 2025 | -657.65% |
| Dec 31, 2024 | 3.33% |
| Sep 30, 2024 | -67.33% |
| Jun 30, 2024 | -58.46% |
| Mar 31, 2024 | -48.55% |